88345-92-0

Basic information

• Product Name: Pyridine, 5-bromo-2-(4-chlorophenyl)-
• CAS NO: 88345-92-0
• Molecular Formula: C11H7BrClN
• Molecular Weight: 268.54
• Mol File: 88345-92-0.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Pyridine, 5-bromo-2-(4-chlorophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Pyridine, 5-bromo-2-(4-chlorophenyl)-(88345-92-0)
• EPA Substance Registry System: Pyridine, 5-bromo-2-(4-chlorophenyl)-(88345-92-0)

Safety Data

• Hazardous Substances Data: 88345-92-0(Hazardous Substances Data)

Upstream product

• 223463-13-6 2-iodo-5-bromopyridine 
• 1679-18-1 4-Chlorophenylboronic acid 
• 624-28-2 2,5-dibromopyridine 
• 5575-51-9 tris(4-chlorophenyl)bismuthane 
• 626-55-1 3-Bromopyridine 
• 106-47-8 4-chloro-aniline 
• 90731-83-2 3-bromo-1-(phenoxycarbonyl)pyridinium chloride 
• 873-77-8 (4-chlorphenyl)magnesium bromide 
• 151073-70-0 (4-chloro)phenylzinc iodide 

Relevant articles and documents

Synthesis of 2-Arylpyridines and 2-Arylbipyridines via Photoredox-Induced Meerwein Arylation with in Situ Diazotization of Anilines

We report herein a sustainable method for the preparation of 2-arylpyridines through C-H arylation of pyridines using in situ formed diazonium salts (from commercially available aromatic amines) in the presence of a photoredox catalyst under blue light-emitting diode (LED) irradiation. The reaction is tolerant to a wide range of functional groups (e.g., halogen, nitrile, formyl, acetyl, ester). Applications to the C-H bond arylation of bipyridine ligands is also presented.

A study on the selectivity of arylzinc reagents in cross-coupling reactions with chemically equivalent and pseudo-equivalent dibromopyridines

-

NOVEL ALKYNE COMPOUNDS HAVING AN MCH ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING THESE COMPOUNDS

The invention relates to alkyne compounds of general formula (I), in which groups and residues A, B, W, X, Y, Z, R1 and R2 have the meanings as cited in Claim 1. The invention also relates to medicaments containing at least one inventive alkyne. The MCH receptor antagonistic effect renders the inventive medicaments suitable for treating metabolic disorders and/or eating disorders, in particular, obesity, bulimia, anorexia, hyperphagia and diabetes.